Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2018

View Archived Issues

FDA awards orphan drug designation to brincidofovir for the treatment of smallpox

Biogen enters agreement to acquire stroke drug candidate from TMS

MannKind announces completion of phase I study of TreT in pulmonary arterial hypertension

Vonoprazan noninferior to lansoprazole in phase III erosive esophagitis study

Researchers unveil TMEM16A as potential therapeutic target for cystic fibrosis

RDX-023: A non-bile acid FXR agonist with potential for improved safety

Bristol-Myers Squibb describes integrin alpha-V antagonists

FDA and EMA accepts regulatory submissions of talazoparib for review

Guangdong Longchuangji Pharmacy Co. presents Lactobacillus rhamnosus strain

FDA grants orphan drug designation to olinciguat for sickle cell disease

Beijing Gegen Biotechnology, Yicon Medical Science and Technology Co. patent anti-EGFR antibodies

FDA approves Mircera for pediatric use

Seoul National University creates adenoviral vector encoding CRY1

Mitochondrial aging in directly induced neurons may help understand neurodegenerative diseases

Roche patents anti-pY796-DDR1 antibodies

TET2 disruption improves antitumor activity of CAR T-cell therapy in a CLL patient

MyoKardia opens phase III study of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy

First celiac disease model with a humanized immune system reported

Luye Pharma and Elpis expand collaboration in immuno-oncology

Minesapride shows clinical efficacy in irritable bowel syndrome with constipation

Updated interim data from phase I/II study of lumasiran for primary hyperoxaluria type 1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...